Solifenacin Succinate (YM905)是一种毒蕈碱受体拮抗剂,对 M3、M1 和 M2 受体的亲和力依次递减。
|
英文别名 (English Synonym) |
Solifenacin succinate |
|
中文名称 (Chinese Name) |
索非那新琥珀酸盐 |
|
靶点 (Target) |
Muscarinic Receptor |
|
通路 (Pathway) |
Neuroscience |
|
CAS号 (CAS NO.) |
242478-38-2 |
|
分子式 (Formula) |
C27H32N2O6 |
|
分子量 (Molecular Weight) |
480.55 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Krishna SR, Rao BM, Rao NS. A validated rapid stability-indicating method for the determination of related substances in solifenacin succinate by ultra-fast liquid chromatography. J Chromatogr Sci. 2010 Nov,48(10):807-10. doi: 10.1093/chromsci/48.10.807. PMID: 21044410.[2]Ohtake A, Sato S, Sasamata M, Miyata K. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes. J Pharmacol Sci. 2010,112(2):135-41. doi: 10.1254/jphs.09r13fm. Epub 2010 Feb 4. PMID: 20134114.
